Shots:
- SciNeuro has entered into a global licensing & collaboration deal with Novartis to advance its amyloid beta-targeted antibody program for Alzheimer’s disease
- The program has identified de novo antibody candidates using SciNeuro’s blood–brain barrier shuttle tech, with Novartis leading global development & commercialization after collaboration on early development
- As per the deal, SciNeuro will receive $165M upfront, research funding & ~$1.5B in development, regulatory, & commercial milestones, with tiered royalties; closing expected in H1’26
Ref: PRnewswire | Image: SciNeuro & Novartis | Press Release
Related News: Novartis and Relation Therapeutics Ink ~$1.75B Atopic Disease Target-Discovery Alliance
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
